Typhoid Vaccine, Purified Polysaccharide Antigen

Registered South African indications:

• Active immunisation against typhoid fever caused by Salmonella enterica serovar Typhi (S. typhi) in adults or children ≥2 years of age
  - Intended both for the inhabitants of endemic zones and for persons travelling to endemic areas, migrants, health care workers, catering and food industry professionals and military personnel

Contraindications

• Hypersensitivity to the active ingredient or any of its excipients
• Hypersensitivity after previous administration of the vaccine
• Vaccination must be postponed in case of febrile or acute diseases

Cautions

• Pregnancy
• Breastfeeding
• Renal impairment
• Hepatic impairment
• Thrombocytopaenia
• Bleeding disorders or history thereof
• Congenital or acquired immunodeficiency
• History of needle-syncope (fainting as a psychogenic response to a needle)

Forms avail. in SA and covered in this monograph: inj

South African registered indications and dosages

Active immunisation against typhoid fever caused by Salmonella enterica serovar Typhi (S. typhi) in adults or children ≥2 years of age
- Intended both for the inhabitants of endemic zones and for persons travelling to endemic areas, migrants, health care workers, catering and food industry professionals and military personnel

• IM: 0.5ml, as a single injection

The preferred route of administration for this vaccine is intramuscular although it may also be given subcutaneously

Revaccination should be carried out every 3 years if the subject is still exposed to the risk

Forms avail. in SA and covered in this monograph: inj

South African registered indications and dosages

Active immunisation against typhoid fever caused by Salmonella enterica serovar Typhi (S. typhi) in adults or children ≥2 years of age
- Intended both for the inhabitants of endemic zones and for persons travelling to endemic areas, migrants, health care workers, catering and food industry professionals and military personnel

Younger than 2 years

• Not established for use

Older than 2 years

• See adult dosage

The preferred route of administration for this vaccine is intramuscular although it may also be given subcutaneously

Revaccination should be carried out every 3 years if the subject is still exposed to the risk

Pregnancy 

• Caution; not recommended
• Animal reproduction studies have not been conducted with typhoid vaccine
• Data on the use of this vaccine in pregnant women are limited. Therefore the administration of the vaccine during pregnancy is not recommended
• Typhoid vaccine should be given to pregnant women only if clearly needed and following an assessment of the risks and benefits

Breastfeeding 

• Caution; not recommended
• It is not known whether this vaccine is excreted in human milk. Caution must be exercised when the typhoid vaccine is administered to a nursing mother

Renal Impairment

• Caution; no information available

Hepatic Impairment

• Caution; no information available

Elderly

• No dose adjustment recommended

Porphyria Information

• Probably not porphyrinogenic (PNP)

Central Nervous System Disorders

• Headache
• Malaise

Gastrointestinal Disorders

• Nausea

Skin and Subcutaneous Tissue Disorders

• Itching

Immune, Blood and Lymphatic System Disorders

• Fever
• General ache
• Anaphylaxis
• Allergic reactions
• Urticaria

No information available

None routine

Typhoid vaccine contains purified Vi capsular polysaccharide of Salmonella typhi (Ty 2 strain). Immunity appears within 2-3 weeks after injection and lasts around 3 years.

Injection (per 0.5ml) 25μg

• Typherix (GSK) originator
• Typhim Vi (Sanofi) originator